期刊文献+

肿瘤-睾丸抗原CT45-5的表达纯化及多克隆抗体的制备 被引量:2

Expression and purification of cancer/testis antigen 45-5 and preparation of its polyclonal antibody
原文传递
导出
摘要 目的:原核表达、纯化肿瘤-睾丸抗原CT45-5基因,并制备多克隆抗体,以研究其在Fhit特异的信号通路中的作用。方法:设计出特异针对CT45-5的引物,通过RT-PCR扩增出CT45-5的编码基因,测序正确后插入到含GST基因的原核表达载体pGEX-KG中,以IPTG诱导表达,并经谷胱甘肽琼脂糖珠纯化融合蛋白;用纯化的蛋白免疫小鼠制备多克隆抗体,经ELISA测定抗体的效价,Western印迹鉴定抗体的特异性。结果:原核表达和纯化了CT45-5,并获得了其多克隆抗体,抗体效价达到1∶12800,Western印迹结果显示,该抗血清能够特异识别原核及真核细胞表达的CT45-5蛋白。结论:肿瘤-睾丸抗原CT45-5能够诱导小鼠产生具有较高效价和特异性的多克隆抗体,为进一步研究CT45-5的功能奠定了基础。 Objective:To express and purify cancer/testis antigen 45-5 ( CT45-5 ) in E. coli, and prepare the polyclonal antibody against CT45-5 so as to study its function in the specific Fhit signal pathways. Methods:Specific primers were used to amplify CT45-5 full length gene by RT-PCR, then the gene was inserted into the vector pGEX-KG containing GST gene. GST-CT45-5 fhsion protein was expressed in E. coli, and purified by using glutathione sepharose 4B. Then anti-CT45- 5 antiserum was prepared in mice, the titer was determined by ELISA and the specificity was identified by Western blot. Results:CT45-5 was expressed and purified, and the polyclonal antibody against CT45-5 was prepared. The titer of this anti- body was about 1:12 800, and CT45-5 expressed in prokaryotic and eukaryotic cells could be recognized by this antiserum. Conclusion: CT45-5 can induce the effective and specific polyclonal antibody in mice, which sheds light on the function of cancer/testis antigen 45-5.
出处 《军事医学科学院院刊》 CSCD 北大核心 2009年第4期333-336,共4页 Bulletin of the Academy of Military Medical Sciences
基金 国家自然科学基金项目(No.30770651 30670616 30370441) 国家重点基础研究发展计划项目(No.2005CB522506 2007CB914604) 国家"十一五"支撑项目(No.2006BAI23B02)
关键词 肿瘤-睾丸抗原CT45-5 表达纯化 多克隆抗体 cancer/testis antigen 45-5 expression and purification polyclonal antibody
  • 相关文献

参考文献10

  • 1Scanlan MJ,Simpson AJ,Old LJ,et al.The cancer/ testis genes:review,standardization,and commentary[J].Cancer Immun,2004,4(1):1-15.
  • 2Simpson AJ,Caballero OL,Jungbluth A,et al.Cancer/testis antigens,gametogenesis and cancer[J].Nat Rev Cancer,2005,5(8):615-625.
  • 3Ross MT,Grafham DV,Coffey AJ,et al.The DNA sequence of the human X chromosome[J].Nature,2005,434(7031):325-337.
  • 4Sahin U,Tureci O,Chen YT,et al.Expression of multiple cancer/testis(CT) antigens in breast cancer and melanoma:basis for polyvalent CT vaccine strategies[J].Int J Cancer,1998,78(3):387-389.
  • 5Sharma P,Shen Y,Wen S,et al.Cancer-testis antigens:expression and correlation with survival in human urothelial carcinoma[J].Clin Cancer Res,2006,12(18):5442-5447.
  • 6Tajima K,Obata Y,Tamaki H,et al.Expression of cancer/testis (CT) antigens in lung cancer[J].Lung Cancer,2003,42(1):23-33.
  • 7Gnjatic S,Nishikawa H,Jungbluth AA,et al.NY-ESO-1:review of an immunogenic tumor antigen[J].Adv Cancer Res,2006,95(1):1-30.
  • 8Heidebrecht HJ,Claviez A,Kruse ML,et al.Characterization and expression of CT45 in Hodgkin′s lymphoma[J].Clin Cancer Res,2006,12(16):4804-4811.
  • 9Chen YT,Hsu M,Lee P,et al.Cancer/testis antigen CT45:analysis of mRNA and protein expression in human cancer[J].Int J Cancer,2009,124(12):2893-2898.
  • 10Andrade VC,Vettore AL,Regis Silva MR,et al.Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma[J].Exp Hematol,2009,37(4):446-449.

同被引文献13

  • 1Chen Y T, Russ D S, Chiu R, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast caneers[J]. PLuS One, 2011,6(3): el7876.
  • 2Scanlan M J, Gure A O, Jungbluth A A, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy[J], Immanol Rev, 2002,188:22-32.
  • 3Chen Y T, Chadburn A, Lee P, et al. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas[J]. Proc Natl Acad Sei USA, 2010,107(7): 3093-3098.
  • 4Lira S H, Ztmng Y, Zhang J, et al. Cancer-testis antigens: the current status on antigen regulation and potential clinieal use[J]. Am J Blood Res, 2012,2( 1):29-35.
  • 5Caballero O L, Chen Y T. Cancer/testis(CT) antigens: potential targets for immunotherapy[J]. Cancer Sci, 2009,100:2014- 2021.
  • 6Chen Y T, Scanlan M J, Venditti C A, et al. Identification of cancer_testis-antigen genes by massively parallel signature sequencing[J]. Proc Natl Acad Sci USA, 2005,102(22):7940- 7945.
  • 7Chen Y T, Hsu M, Lee P, et al. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer[J]. lnt J Cancer, 2009,124:2893-2898.
  • 8Hu B, Han S Y, Wang X, et al. Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHKI pathway [J]. J Cell Physiol, 2005,202(2):518-523.
  • 9Hu B, Wang H, Wang X, et al. Fhit and CHK1 have opposing effects on homologous recombination repair[J]. Cancer Res, 2005,65(19):8613-8616.
  • 10Lu L, Hu B, Yu F, et al. Low dose radiation-induced adaptive response preventing HPRT mutation is Fhit independent [J]. Int J Radiat Biol, 2009,85(6):532-537.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部